| review article | Q7318358 |
| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10590501.2014.877645 |
| P698 | PubMed publication ID | 24598039 |
| P50 | author | Chin-Hsiao Tseng | Q56985561 |
| P2093 | author name string | Chin-Hsiao Tseng | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study | Q24654974 | ||
| Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis | Q27002540 | ||
| The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not? | Q28390036 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort | Q31045562 | ||
| Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 | ||
| Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies | Q33774754 | ||
| Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study | Q34035766 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients | Q34329426 | ||
| Polychlorinated biphenyls and cancer: an epidemiological assessment. | Q34344579 | ||
| Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies | Q34353701 | ||
| Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. | Q34535741 | ||
| Thyroid cancer risk is not increased in diabetic patients | Q34541648 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies | Q34599224 | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Q34609508 | ||
| Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies | Q34627077 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Pioglitazone, bladder cancer, and detection bias | Q34805758 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology | Q35162366 | ||
| Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease | Q35556028 | ||
| Polycyclic aromatic hydrocarbons and digestive tract cancers: a perspective | Q35637318 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer | Q36011482 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Diabetes but not insulin is associated with higher colon cancer mortality | Q36175076 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. | Q36365241 | ||
| Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| Meta-analysis in surgery: methods and limitations | Q36658731 | ||
| Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights | Q37115436 | ||
| Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies | Q37280771 | ||
| Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. | Q37366707 | ||
| Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications | Q37394037 | ||
| Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. | Q37577159 | ||
| Diabetes mellitus, hyperglycaemia and cancer | Q37765725 | ||
| Bladder cancer in 2010: how far have we come? | Q37766697 | ||
| Female bladder cancer: incidence, treatment, and outcome | Q37769090 | ||
| Glucose metabolism disorders and the risk of cancer. | Q37859317 | ||
| A current global view of environmental and occupational cancers | Q37935012 | ||
| Exposure to formaldehyde and its potential human health hazards | Q37959567 | ||
| Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how? | Q37968638 | ||
| Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? | Q37994235 | ||
| Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence | Q38000088 | ||
| Association between pioglitazone and urothelial bladder cancer | Q38012891 | ||
| Thyroid disrupting chemicals in plastic additives and thyroid health | Q38018098 | ||
| Nutritional chemoprevention of urinary tract tumors (UTT) induced by lithogenic agents: risk for UTT in children exposed to melamine-contaminated milk formulas. | Q38018099 | ||
| Guidelines for asbestos remediation at Italian superfund sites | Q38042668 | ||
| Environmental toxicants--induced epigenetic alterations and their reversers | Q38061183 | ||
| Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies | Q38061184 | ||
| Pioglitazone and cancer: angel or demon? | Q38070732 | ||
| Pioglitazone--do we really need it to manage type 2 diabetes? | Q38091789 | ||
| Antitumor effects of energy restriction-mimetic agents: thiazolidinediones. | Q38101228 | ||
| Phototoxicity of herbal plants and herbal products | Q38136247 | ||
| A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? | Q38429541 | ||
| Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cel | Q38454134 | ||
| The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model | Q39202985 | ||
| Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells | Q39448285 | ||
| Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan. | Q39665426 | ||
| Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan | Q40707157 | ||
| Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. | Q41892776 | ||
| Epidemiology of primary liver cancer in Serbia and possible connection with cyanobacterial blooms. | Q42270586 | ||
| Incretin-based therapies: facing the realities of benefits versus side effects | Q42921290 | ||
| Optimal anthropometric factor cutoffs for hyperglycemia, hypertension and dyslipidemia for the Taiwanese population | Q43201333 | ||
| Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan | Q43748015 | ||
| Channeling bias in the interpretation of drug effects | Q43822996 | ||
| Bias: considerations for research practice | Q43836796 | ||
| Pioglitazone and risk of bladder cancer: clarification of the design of the French study | Q43838222 | ||
| Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. | Q44060581 | ||
| Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. | Q44132072 | ||
| Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study | Q44980532 | ||
| Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes | Q45040932 | ||
| Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. | Q45974572 | ||
| Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. | Q46868396 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. | Q51167323 | ||
| Diabetes and thyroid cancer mortality: a 12-year prospective follow-up of Taiwanese. | Q51211051 | ||
| Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. | Q51501226 | ||
| Evaluating Medication Effects Outside of Clinical Trials: New-User Designs | Q52956338 | ||
| New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. | Q53102072 | ||
| Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. | Q53102462 | ||
| Carcinogenicity of some drugs and herbal products | Q58815362 | ||
| P433 | issue | 1 | |
| P921 | main subject | bladder cancer | Q504775 |
| P1104 | number of pages | 45 | |
| P304 | page(s) | 1-45 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews | Q15724521 |
| P1476 | title | A review on thiazolidinediones and bladder cancer in human studies | |
| P478 | volume | 32 |
| Q34181385 | A Review on the Relationship between SGLT2 Inhibitors and Cancer. |
| Q38388920 | An updated review on cancer risk associated with incretin mimetics and enhancers |
| Q46360731 | Association of Metformin Use and Survival Outcome in Women With Cervical Cancer |
| Q33808884 | Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. |
| Q36209639 | Factors Associated with Cancer- and Non-Cancer-Related Deaths among Taiwanese Patients with Diabetes after 17 Years of Follow-Up |
| Q46603087 | Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay |
| Q55109644 | Harnblasenkrebs |
| Q37274957 | Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus |
| Q34323510 | Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes |
| Q37644891 | Metformin use and cervical cancer risk in female patients with type 2 diabetes |
| Q55356554 | Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study. |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q35639510 | Polycystic ovary syndrome: chemical pharmacotherapy |
| Q35077354 | Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese |
| Q37709423 | Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus |
| Q38941094 | Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes |
| Q37745926 | Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes |
| Q35838633 | Type 2 Diabetes Mellitus and Kidney Cancer Risk: A Retrospective Cohort Analysis of the National Health Insurance |
| Q35782192 | Use of Insulin and Mortality from Breast Cancer among Taiwanese Women with Diabetes |
Search more.